Trials / Terminated
TerminatedNCT01866904
Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients
TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 9,284 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
THis study is intended to provide contemporary data on the burden of disease in patients 1 to 3 years post-MI, including a description of patient characteristics, current treatment patterns, rate of major CV events, and healthcare resource utilization in a 'real world' patient population at high atherothrombotic risk.
Detailed description
TIGRIS is a multinational, multi-centre, observational, prospective, longitudinal cohort study which will include stable CAD patients with history of MI 1-3 years ago and high risk of developing atherothrombotic events in a real world setting. The follow-up period is 3 years. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. Patients will not receive experimental intervention or experimental treatment as a consequence of their participation in the study.
Conditions
Timeline
- Start date
- 2013-06-19
- Primary completion
- 2017-03-31
- Completion
- 2017-03-31
- First posted
- 2013-06-03
- Last updated
- 2018-09-04
Locations
309 sites across 25 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, China, Colombia, Denmark, Finland, France, Germany, India, Italy, Japan, Mexico, Netherlands, Norway, Portugal, Romania, South Korea, Spain, Turkey (Türkiye), United Kingdom, Venezuela
Source: ClinicalTrials.gov record NCT01866904. Inclusion in this directory is not an endorsement.